Period | Year | Apixaban | Edoxaban | Rivaroxaban | Dabigatran etexilate | Total | ||||
Patient count | % | Patient count | % | Patient count | % | Patient count | % | |||
March–May | 2020 | 6700 | 33.5 | 7620 | 38.1 | 5550 | 27.8 | 120 | 0.6 | 19 990 |
2019 | 3510 | 51.1 | 1040 | 15.2 | 2190 | 31.9 | 120 | 1.8 | 6860 | |
June–August | 2020 | 2550 | 40.3 | 2110 | 33.4 | 1620 | 25.6 | 40 | 0.6 | 6320 |
2019 | 2900 | 49.5 | 1110 | 18.9 | 1760 | 30 | 90 | 1.6 | 5860 |
Number and percentage of warfarin patients switched to each of the four types of DOAC between March and May 2020 compared with 2019, and similarly for June–August, for people who were prescribed warfarin during the previous 3-month period. Patient counts are rounded to the nearest 10. Percentages may not add to exactly 100 due to rounding.
DOAC, direct-acting oral anticoagulant.